Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAYNIER MOYA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124288980
CMS profile
278302
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$15.30

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $15.30 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Exact Sciences Corporation $15.30 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAYNIER MOYA

NPI 1124288980 · CMS profile ID 278302

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124288980?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124288980?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124288980?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124288980?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $15.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exact Sciences Corporation $15.3009/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235445809 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $128.50 2
PY2023 $1,741.44 2
PY2025 $15.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,567,242.14 108
PY2024 Recipient $1,161.49 6
PY2024 Principal investigator $5,059,140.87 296
PY2023 Recipient $2,506.25 1
PY2023 Principal investigator $14,127,127.37 743
PY2022 Recipient $24,618.00 1
PY2022 Principal investigator $15,001,316.81 131
PY2021 Principal investigator $6,255,399.36 48
PY2020 Principal investigator $653,923.11 62
PY2019 Principal investigator $748,551.83 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

302 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $3,833.66 12/30/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147157453
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,082.00 12/19/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235416
Principal investigator 1 Janssen Research & Development, LLC $4,410.00 12/16/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958239
Principal investigator 1 SANOFI US SERVICES INC. $21,102.00 12/16/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712343
Principal investigator 1 SANOFI US SERVICES INC. $31,654.70 12/16/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128712365
Principal investigator 1 Janssen Research & Development, LLC $401,010.00 12/13/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958219
Principal investigator 1 Chiesi USA, Inc. $7,931.52 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148225728
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225778
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225780
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225782
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225784
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225786
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225788
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225790
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225792
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225794
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225796
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225798
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225800
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225802
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225804
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225806
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225808
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225810
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225812
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225814
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225816
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225818
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225820
Principal investigator 1 Chiesi USA, Inc. $787.50 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225822
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225824
Principal investigator 1 Chiesi USA, Inc. $613.75 12/11/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225826
Principal investigator 1 SANOFI US SERVICES INC. $4,968.00 12/03/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712359
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 11/27/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958203
Principal investigator 1 Janssen Research & Development, LLC $3,575.00 11/27/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958209
Principal investigator 1 Janssen Research & Development, LLC $3,150.00 11/27/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958213
Principal investigator 1 Janssen Research & Development, LLC $13,850.00 11/27/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958233
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $24,121.50 11/27/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235412
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,696.50 11/27/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235414
Principal investigator 1 SANOFI US SERVICES INC. $7,750.00 11/25/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712331
Principal investigator 1 Chiesi USA, Inc. $3,925.88 11/15/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225136
Principal investigator 1 Chiesi USA, Inc. $3,925.88 11/15/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225138
Principal investigator 1 Chiesi USA, Inc. $3,925.88 11/15/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225140
Principal investigator 1 Chiesi USA, Inc. $3,925.88 11/15/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225142
Principal investigator 1 Chiesi USA, Inc. $3,925.88 11/15/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148225144
Principal investigator 1 Chiesi USA, Inc. $6,955.20 11/13/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148224936
Principal investigator 1 Janssen Research & Development, LLC $5,820.00 11/13/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958215
Principal investigator 1 Janssen Research & Development, LLC $107,307.00 11/13/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958225
Principal investigator 1 SANOFI US SERVICES INC. $16,300.00 11/12/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128712333
Principal investigator 1 SANOFI US SERVICES INC. $247,024.10 11/12/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128712335
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 11/06/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958201
Principal investigator 1 Janssen Research & Development, LLC $2,760.00 11/06/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958217
Principal investigator 1 Janssen Research & Development, LLC $9,500.00 11/06/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958229
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 10/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235432
Principal investigator 1 SANOFI US SERVICES INC. $5,659.00 10/28/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712315
Principal investigator 1 Chiesi USA, Inc. $3,925.88 10/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148224216
Principal investigator 1 Chiesi USA, Inc. $3,925.88 10/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148224218
Principal investigator 1 Chiesi USA, Inc. $3,925.88 10/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148224220
Principal investigator 1 Chiesi USA, Inc. $3,925.88 10/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148224222
Principal investigator 1 Chiesi USA, Inc. $3,925.88 10/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148224224
Principal investigator 1 Chiesi USA, Inc. $3,925.88 10/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148224226
Principal investigator 1 Janssen Research & Development, LLC $6,426.00 10/16/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958223
Principal investigator 1 SANOFI US SERVICES INC. $19,250.00 10/15/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712317
Principal investigator 1 Chiesi USA, Inc. $8,419.68 10/09/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223928
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,506.00 10/09/2024 Non-covered Recipient Entity
Pines Care Research Center, Llc
Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1123479227
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $181,204.55 10/04/2024 Non-covered Recipient Entity
Elias Research Associates Llc
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1123477138
Principal investigator 1 SANOFI US SERVICES INC. $35,266.00 10/02/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712349
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $73,225.44 09/27/2024 Non-covered Recipient Entity
Pines Care Research Center, Llc
Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) No dispute reported 06/30/2026 1123479225
Principal investigator 1 ModernaTX, Inc. $106,472.92 09/25/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147157451
Principal investigator 1 Chiesi USA, Inc. $19,332.00 09/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148223066
Principal investigator 1 SANOFI US SERVICES INC. $9,525.00 09/16/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712167
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 09/13/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958199
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $42,786.90 09/12/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235378
Principal investigator 1 SANOFI US SERVICES INC. $8,875.00 08/26/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712301
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,771.96 08/21/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER, LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110840014
Principal investigator 1 SANOFI US SERVICES INC. $5,700.00 08/19/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712141
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,778.30 08/15/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235376
Principal investigator 1 Janssen Research & Development, LLC $14,400.00 08/14/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958237
Principal investigator 1 Chiesi USA, Inc. $24,358.32 08/09/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148222206
Principal investigator 1 ModernaTX, Inc. $130,243.36 08/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147157449
Principal investigator 1 Chiesi USA, Inc. $6,665.19 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221762
Principal investigator 1 Chiesi USA, Inc. $397.50 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221764
Principal investigator 1 Chiesi USA, Inc. $397.50 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221766
Principal investigator 1 Chiesi USA, Inc. $6,665.19 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221768
Principal investigator 1 Chiesi USA, Inc. $1,882.69 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221770
Principal investigator 1 Chiesi USA, Inc. $397.50 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221772
Principal investigator 1 Chiesi USA, Inc. $6,665.19 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221774
Principal investigator 1 Chiesi USA, Inc. $397.50 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221776
Principal investigator 1 Chiesi USA, Inc. $1,882.69 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221778
Principal investigator 1 Chiesi USA, Inc. $6,665.19 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221780
Principal investigator 1 Chiesi USA, Inc. $397.50 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221782
Principal investigator 1 Chiesi USA, Inc. $6,665.19 07/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148221784
Principal investigator 1 Janssen Research & Development, LLC $13,725.00 07/29/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958235
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $22,951.50 07/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235374
Principal investigator 1 SANOFI US SERVICES INC. $12,625.00 07/15/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712137
Principal investigator 1 Chiesi USA, Inc. $20,751.12 07/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148221230
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 07/03/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235430
Principal investigator 1 Janssen Research & Development, LLC $20,862.00 06/26/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958207
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $127,774.00 06/22/2024 Non-covered Recipient Entity
Pines Care Research Center LLC
Phase II dose finding/PoCC in CKD No dispute reported 06/30/2026 1101069397
Recipient SANOFI US SERVICES INC. $27.47 06/22/2024 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128713587
Recipient SANOFI US SERVICES INC. $74.86 06/22/2024 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128713589
Recipient SANOFI US SERVICES INC. $84.97 06/22/2024 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128713591
Recipient SANOFI US SERVICES INC. $295.27 06/22/2024 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128713593
Recipient SANOFI US SERVICES INC. $309.94 06/22/2024 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128713595
Recipient SANOFI US SERVICES INC. $368.98 06/22/2024 Covered Recipient Physician A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1128713597
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,811.85 06/14/2024 Non-covered Recipient Entity
Pines Care Research Center, Llc
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1123479221
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,746.12 06/14/2024 Non-covered Recipient Entity
Pines Care Research Center, Llc
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1123479223
Principal investigator 1 Eli Lilly and Company $1,707.52 06/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137364259
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,702.00 06/06/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235340
Principal investigator 1 Chiesi USA, Inc. $20,877.20 06/05/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148220286
Principal investigator 1 GlaxoSmithKline, LLC. $3,591.26 06/03/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518763
Principal investigator 1 Janssen Research & Development, LLC $10,125.00 05/21/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958231
Principal investigator 1 Eli Lilly and Company $3,051.00 05/07/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137364261
Principal investigator 1 Chiesi USA, Inc. $19,968.92 05/03/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148219324
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $66,734.20 05/02/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235338
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518755
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518757
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518759
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518765
Principal investigator 1 GlaxoSmithKline, LLC. $273.02 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518767
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518769
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542047
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542049
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542051
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542053
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542055
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542057
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542059
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542061
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542063
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542065
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542067
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542069
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542071
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542073
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542075
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127542077
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127547674
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127547676
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127547678
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127547680
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127547682
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549104
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549114
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549116
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549118
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549120
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549122
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549124
Principal investigator 1 GlaxoSmithKline, LLC. $1,365.10 05/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549128
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219126
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219128
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219130
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219132
Principal investigator 1 Chiesi USA, Inc. $397.50 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219134
Principal investigator 1 Chiesi USA, Inc. $397.50 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219136
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219138
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219140
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/26/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148219142
Principal investigator 1 Janssen Research & Development, LLC $10,350.00 04/19/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958227
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 04/17/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235428
Principal investigator 1 SANOFI US SERVICES INC. $10,710.00 04/15/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712119
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218443
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218445
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218447
Principal investigator 1 Chiesi USA, Inc. $397.50 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218449
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218451
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218453
Principal investigator 1 Chiesi USA, Inc. $397.50 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218455
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218457
Principal investigator 1 Chiesi USA, Inc. $397.50 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218459
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218461
Principal investigator 1 Chiesi USA, Inc. $397.50 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218463
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218465
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218467
Principal investigator 1 Chiesi USA, Inc. $397.50 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218469
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218471
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218473
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218475
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218477
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218479
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218481
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218483
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218485
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218487
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218489
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218491
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218493
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218495
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218497
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218499
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218501
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218503
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218505
Principal investigator 1 Chiesi USA, Inc. $397.50 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218507
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218509
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218511
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218513
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218515
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218517
Principal investigator 1 Chiesi USA, Inc. $6,665.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218519
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218521
Principal investigator 1 Chiesi USA, Inc. $1,273.19 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218523
Principal investigator 1 Chiesi USA, Inc. $6,488.94 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218525
Principal investigator 1 Chiesi USA, Inc. $2,652.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218527
Principal investigator 1 Chiesi USA, Inc. $1,882.69 04/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218529
Principal investigator 1 Janssen Research & Development, LLC $25,650.00 04/09/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958205
Principal investigator 1 GlaxoSmithKline, LLC. $9,828.72 04/01/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127549126
Principal investigator 1 Chiesi USA, Inc. $51,177.20 03/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148217535
Principal investigator 1 ModernaTX, Inc. $167,071.49 03/27/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147157447
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,849.62 03/21/2024 Non-covered Recipient Entity
Elias Research Associates Llc
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1123477136
Principal investigator 1 ModernaTX, Inc. $598,211.10 03/21/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147157445
Principal investigator 1 PFIZER INC. $324,445.40 03/19/2024 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131099551
Principal investigator 1 SANOFI US SERVICES INC. $10,350.00 03/11/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712097
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33,961.20 03/07/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235328
Principal investigator 1 PFIZER INC. $9,590.00 03/06/2024 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131099545
Principal investigator 1 Bavarian Nordic A/S $1,800.00 02/29/2024 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119666024
Principal investigator 1 Bavarian Nordic A/S $1,500.00 02/29/2024 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119666026
Principal investigator 1 Bavarian Nordic A/S $850.00 02/29/2024 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119666030
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 02/28/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235426
Principal investigator 1 Janssen Research & Development, LLC $21,920.00 02/27/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958221
Principal investigator 1 SANOFI US SERVICES INC. $15,525.00 02/12/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712083
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 02/06/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235424
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215332
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215334
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215336
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215338
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215340
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215342
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215344
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215346
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215348
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215352
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215354
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215356
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215358
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215360
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215362
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215364
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215366
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215368
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215370
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215372
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215374
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215376
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215378
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215380
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215382
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215384
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215386
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215388
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215390
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215394
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215396
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215398
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215400
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215402
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215404
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215406
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215408
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215410
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215412
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215416
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215418
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215420
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215422
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215424
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215426
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215428
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215430
Principal investigator 1 Chiesi USA, Inc. $1,273.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215432
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215434
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215436
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215438
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215440
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215442
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215444
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215446
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215448
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215450
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215452
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215454
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215456
Principal investigator 1 Chiesi USA, Inc. $397.50 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215458
Principal investigator 1 Chiesi USA, Inc. $1,882.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215460
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215462
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215464
Principal investigator 1 Chiesi USA, Inc. $2,652.69 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215466
Principal investigator 1 Chiesi USA, Inc. $6,488.94 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215468
Principal investigator 1 Chiesi USA, Inc. $6,665.19 01/29/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148215470
Principal investigator 1 GlaxoSmithKline, LLC. $533,483.06 01/24/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1127518761
Principal investigator 1 SANOFI US SERVICES INC. $26,440.00 01/22/2024 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712073
Principal investigator 1 Janssen Research & Development, LLC $16,650.00 01/18/2024 Non-covered Recipient Entity
Pines Care Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078958211
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $59,530.90 01/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235324
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,893.30 01/18/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235326
Principal investigator 1 PFIZER INC. $233,172.50 01/17/2024 Non-covered Recipient Entity
Pines Care Research Center LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1131106408
Principal investigator 1 ModernaTX, Inc. $133,673.94 01/16/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC.
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147157443
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 01/12/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235422
Principal investigator 1 Chiesi USA, Inc. $30,256.28 01/10/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148214179
Principal investigator 1 Bavarian Nordic A/S $54,000.00 01/09/2024 Non-covered Recipient Entity
Pines Care Research Center, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119666028
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $272.80 01/05/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235420
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $136.40 01/03/2024 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144235418